Ultromics, a developer of AI echocardiography software, has raised $55 million in series C financing, which will go toward expanding its portfolio and U.S. presence.
L&G, Allegis Capital, and Lightrock co-led the funding round, with continued support from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. U.S.-based health systems, including UChicago Medicine's venture investment vehicle, UCM Ventures, and UPMC Enterprises, also participated in the round.
Ultromics uses AI to extract hidden disease signals from standard echocardiograms, aiming for more accurate detection of complex heart conditions without the need for new hardware or disrupting clinical workflows. Its EchoGo platform, cleared by the U.S. Food and Drug Administration (FDA), supports the diagnosis of heart failure with preserved ejection fraction and cardiac amyloidosis.
The company said it is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions. It also highlighted growing adoption and partnerships across flagship institutions, including the University of Chicago Medicine, University Hospitals Cleveland, Northwestern, and the Mayo Clinic.
In late 2024, Ultromics received FDA Breakthrough Device clearance for EchoGo Amyloidosis, followed in 2025 by the launch of EchoGo Score, the latter of which adds AI-driven probability scoring to EchoGo Heart Failure.
![Examples of ultrasound findings and techniques. (A) Images in a 39-year-old male patient with a mass in the left thigh. The mass is heterogeneous on the B-mode US image (compared with the patient in D) and showed increased microvascularity (superb microvascular imaging [SMI]) and shear-wave elastography (SWE) values. Undifferentiated pleomorphic sarcoma was diagnosed at biopsy (with pleomorphic rhabdomyosarcoma in surgical specimen). (B) Images in an 18-year-old male patient with a mass in the left leg. The mass is hypoechoic on the B-mode image, with no other findings suggestive of malignancy. The lesion is in contact with the cortex of the tibia, which is slightly irregular. CT revealed a doubtful anteromedial tibial erosion. The microvascular study demonstrated high vascularization, suggestive of malignancy. Periosteal Ewing sarcoma was diagnosed with both histologic and immunohistochemical confirmation. (C) Images in a 69-year-old female patient with a lump growing on the outside of the left leg. Multiple SWE examinations were performed (please note the high values obtained in the measurements, whereas the color map highlights the stiffness relative to adjacent tissues). SMI showed areas of increased vascularization to target for sampling. Undifferentiated spindle cell sarcoma was diagnosed at biopsy, with residual leiomyosarcoma in the surgical specimen after neoadjuvant therapy. (D) Images in a 56-year-old female patient with a mass in the right thigh. The mass is heterogeneous at both B-mode ultrasound (similar to patient A) and MRI (coronal T2-weighted spectral attenuated inversion recovery [SPAIR]; T1-weighted pre-contrast and postcontrast imaging), which even shows uptake after the administration of paramagnetic contrast material, which is traditionally suggestive of malignancy. Low values at SMI and elastography are suggestive of benignity. Spindle cell lipoma was diagnosed at biopsy, with atypical spindle cell lipomatous tumor in the surgical specimen.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/08/images-radiol250278fig2.APCFLSvX6p.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
